You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Clinical Updates in Evolving Treatment Strategies for Sarcoma

  • Authors:

    Vivek Subbiah, MD; Jean-Yves Blay, MD; Roman Groisberg, MD

  • CME / ABIM MOC Released: 10/31/2019
  • Valid for credit through: 10/31/2020, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists.

The goal of this activity is to improve clinicians' knowledge about emerging approaches for the treatment of sarcoma.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Biological and clinical rationale for emerging and new treatment strategies for sarcoma 
    • Clinical evidence for emerging and new treatment strategies for sarcoma
    • Potential role of emerging multi-targeted and oncogenic driver therapies in the treatment paradigm for sarcoma


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Vivek Subbiah, MD

    Associate Professor
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
    Executive Director, Medical Oncology Research
    MD Anderson Cancer Network® Center
    Medical Director, Clinical Center for Targeted Therapy
    Associate Professor, Division of Pediatrics
    University of Texas MD Anderson Cancer
    Houston, Texas, United States


    Disclosure: Vivek Subbiah, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Helsinn Therapeutics, Inc
    Received grants for clinical research from: Abbvie; Agensys; Alfa-sigma; Amgen; Bayer AG; Berghealth; Boston Biomedical; Blueprint medicines; Celgene; D3; Exelixis; Fujifilm; GlaxoSmithKline; Helsi; Incyte; Inhbrx; Idera Pharma; Loxo oncology; Multivir; Nanocarrier; Northwest Biotherapeutics; Novartis, Vegenics, Pfizer; Pharmamar; Takeda and Roche/ Genentech

  • Jean-Yves Blay, MD

    Directeur Général-General director
    Centre Léon Bérard
    Lyon, France


    Disclosure: Jean-Yves Blay, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer AG; Bristol-Meyers Squibb Company; Deciphera; Novartis; PharmaMar; Roche
    Received grants for clinical research from: Bayer AG; Deciphera; GlaxoSmithKline; Novartis; PharmaMar; Roche 

  • Roman Groisberg, MD

    Assistant Professor –Medical Oncology
    Department of Melanoma and Sarcoma
    Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey


    Disclosure: Roman Groisberg, MD, has disclosed no relevant financial relationships


  • Melinda Tanzola, PhD

    Scientific Director, Medscape, LLC


    Disclosure: Melinda Tanzola, PhD, has disclosed no relevant financial relationships.

CME Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.   

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Clinical Updates in Evolving Treatment Strategies for Sarcoma

Authors: Vivek Subbiah, MD; Jean-Yves Blay, MD; Roman Groisberg, MDFaculty and Disclosures

CME / ABIM MOC Released: 10/31/2019

Valid for credit through: 10/31/2020, 11:59 PM EST


AE = adverse event
ALK = anaplastic lymphoma kinase
ASPS = alveolar soft part sarcoma
CR = complete response
ctDNA = circulating tumor DNA
ESMO = European Society for Medical Oncology
EZH2 = enhancer of zeste homolog 2
FDG = fluorodeoxyglucose
GIST - gastrointestinal stromal tumors
MAPK = mitogen-activated protein kinase
mDOR = median duration of response
mOS = median overall survival
mPFS = median progression-free survival
NaF = sodium fluoride
NGS = next-generation sequencing
NSCLC = non-small cell lung cancer
ORR = overall response rate
OS = overall survival
PAZ = pazopanib
PD = progressive disease
PD-1 = programmed death-1
PDGFR = platelet-derived growth factor receptor
PET = positron emission tomography
PFS = progression-free survival
PI3K = phosphoinositide 3-kinase
PR = partial response
REG = regorafenib
SD = stable disease
siRNA = small interfering RNA
STS = soft tissue sarcoma
TKI = tyrosine kinase inhibitor
TRAE = treatment-related adverse event
TRK = tropomyosin receptor kinase
VEGF = vascular endothelial growth factor
VEGFR2 = vascular endothelial growth factor receptor 2

« Return to: Clinical Updates in Evolving Treatment Strategies for Sarcoma
  • Print